Thursday 16 October, 2025
Objectives: Extending the dosing interval between infliximab infusions has been attempted in patients with Crohn’s disease (CD) and ulcerative colitis…
Read moreAbstracts
Bridging studies: handling covariates models using the Prior approach
Thursday 16 October, 2025
Introduction/Objectives: The PRIOR function in NONMEM stabilizes model estimates toward prior estimates by adding a penalty function on the objective…
Read moreA population pharmacokinetic model of Glimepiride(Amaryl®)
Thursday 16 October, 2025
Objectives: Glimepiride is an oral hypoglycemic agent used to treat type II diabetes mellitus (T2DM). Glimepiride directly stimulates insulin secretion…
Read morePharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery
Thursday 16 October, 2025
Objectives: Movement is an extensively characterised response to noxious stimulus. However, its applicability to assess intraoperative pain has limitations due…
Read moreThe broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management
Thursday 16 October, 2025
Introduction: Despite millions of surgical procedures are performed every year1, multiple areas of perioperative management lack quantitative tools to guide…
Read morePharmacometric Analysis in Support of Dose Optimization for Pemigatinib Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangements
Thursday 16 October, 2025
Objectives: The objectives were to characterize the pemigatinib pharmacokinetics (PK) and exposure-response (E-R) relationships to support the dose recommendation for…
Read moreHow to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors
Thursday 16 October, 2025
Objectives:Mechanism-based inhibition (MBI) is a subtype of enzymatic inhibition in which the enzyme is permanently inactivated by an intermediate reactive…
Read moreApplication of different approaches to generate virtual patient populations for QSP model of Physiologically based pharmacokinetic model of anti-PD-1 therapeutic antibodies
Thursday 16 October, 2025
Introduction: Conventional approach of QSP modelling includes the procedure of fitting of a model output to series of mean data…
Read morePharmacokinetic model development for total and free vancomycin in critically ill children
Thursday 16 October, 2025
Objectives: Vancomycin is an antibiotic agent used against Gram-positive bacterial infections. In order to achieve optimal target concentrations, it is…
Read moreModelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice
Thursday 16 October, 2025
Objectives: Oncogenic rearrangements of neurotrophic tyrosine receptor kinase (NTRK) encode chimeric proteins with constitutive kinase activity, which promote tumour cell…
Read more